VERAXA Biotech lists on Nasdaq via SPAC merger, raises $77.5m
VERAXA Biotech AG has completed its business combination with Voyager Acquisition Corp., a Cantor Fitzgerald-sponsored special purpose acquisition company, and will begin trading on the Nasdaq Capital Market on 11 June 2026 under the ticker symbol "VRXA", with warrants trading separately as "VRXAW". The Zurich-headquartered company, which focuses on bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) for solid tumours, is entering the public markets alongside a financing package totalling up to $77.5 million.
The transaction was approved by Voyager shareholders in March 2026 and by VERAXA shareholders in February. The combined entity will operate under the name VERAXA Biotech AG and is backed by Xlife Sciences AG, a Swiss life sciences incubator, which is listed on SIX Swiss Exchange. No post-money valuation for the combined group was disclosed in the announcement.
The financing and platform
The capital package comprises a $27.5 million senior secured note and a $50 million share purchase agreement, which the company says will fund its BiTAC-TCE and BiTAC-ADC programmes through initial clinical development milestones. VERAXA describes BiTAC (Bi-targeted Tumour-Associated Cytotoxicity) as a conditionally activated, AND-gated targeting approach designed to engage cancer cells expressing two specific antigens simultaneously, while sparing healthy tissue that expresses only one. The company says this dual-antigen selectivity is intended to widen the therapeutic window in solid tumours, where non-exclusive cancer markers have historically complicated the application of TCE therapies.
Early data from VERAXA's lead BiTAC-TCE candidate were presented as posters at the American Association for Cancer Research Annual Meeting 2026 in San Diego. The company reported that the candidate performed as anticipated in both in vitro and in vivo settings, attacking cells with both target molecules while leaving single-antigen-expressing cells intact. The announcement described the results as demonstrating "a superior safety profile and matching efficacy" relative to a conventional TCE. No numerical data, dose levels, or animal model specifications were included in the press release.
Christoph Antz, Ph.D., chief executive and co-founder, said the listing "better positions us to deliver meaningful value to patients with cancer" and frames the BiTAC platform as a launch pad for multiple future programmes, including radioimmunoconjugates and antibody-oligonucleotide conjugates.
Market context
The bispecific TCE and ADC segments are among the most competitive areas in oncology drug development. Several bispecific T-cell engagers have reached regulatory approval in haematological malignancies, including blinatumomab and, more recently, a series of agents targeting BCMA and CD20. However, extending TCE activity to solid tumours remains a significant and largely unsolved challenge, with antigen heterogeneity and on-target off-tumour toxicity representing persistent obstacles.
The ADC field has seen a wave of approvals and multi-billion dollar licensing transactions over the past three years, attracting large-pharma interest from companies including AstraZeneca, Pfizer, and Daiichi Sankyo. VERAXA's entry into the public market at the preclinical-to-clinical transition point places it at an early stage relative to many of its peers. Investors will be watching for a named lead indication, a formal IND filing, and phase 1 dose-escalation data as the near-term catalysts that will test the platform's clinical validity.
The SPAC route to listing has faced increasing scrutiny from the SEC in recent years, with tighter rules on financial projections in de-SPAC transactions. VERAXA's founders were spun out from the European Molecular Biology Laboratory, lending scientific credibility to the platform, though the company remains entirely pre-clinical revenue-generating at this stage.